CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

NCT00004026 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: CT-2584
DRUG: chemotherapy

Sponsor

CTI BioPharma